表 3.
178例免疫治疗NSCLC患者LIPI、iSEND免疫评分与mPFS的关系
Relationship between LIPI, iSEND immune score and mPFS in 178 treated with immunotherapy NSCLC patients
| Predictive models | Group | n | mPFS (mon) | 95%CI |
| NSCLC: non-small cell lung cancer; mPFS: median PFS. | ||||
| LIPI | Good | 56 | 9.9 | 8.453-11.247 |
| Intermediate | 76 | 6.1 | 4.408-7.792 | |
| Poor | 46 | 3.7 | 2.738-4.687 | |
| iSEND | Good | 26 | 9.9 | 7.760-11.940 |
| Intermediate | 119 | 7.0 | 5.716-8.280 | |
| Poor | 33 | 3.5 | 2.583-4.382 | |
| Total | 178 | 6.4 | 5.425-7.454 | |